TransMedics Reports First Quarter 2026 Financial Results
TransMedics Group, Inc. (TMDX) reported first quarter 2026 revenue of $173.9 million, a 21% increase from the same period in 2025. The company also reiterated its full year 2026 revenue guidance of $727 million to $757 million. Key developments included the unveiling of a new organ preservation system and an investment in a European transplant logistics network.
Tickers: $TMDX
Topics: financial results guidance net income product launch revenue growth strategic investment